257 related articles for article (PubMed ID: 12359756)
41. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
42. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
[TBL] [Abstract][Full Text] [Related]
43. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
44. PDGF receptors as targets in tumor treatment.
Ostman A; Heldin CH
Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
[TBL] [Abstract][Full Text] [Related]
45. Design of growth factor antagonists with antiangiogenic and antitumor properties.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6566-73. PubMed ID: 11426641
[TBL] [Abstract][Full Text] [Related]
46. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
47. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.
Baranowska-Kortylewicz J; Abe M; Pietras K; Kortylewicz ZP; Kurizaki T; Nearman J; Paulsson J; Mosley RL; Enke CA; Ostman A
Cancer Res; 2005 Sep; 65(17):7824-31. PubMed ID: 16140951
[TBL] [Abstract][Full Text] [Related]
48. Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.
Onoyama M; Kitadai Y; Tanaka Y; Yuge R; Shinagawa K; Tanaka S; Yasui W; Chayama K
Neoplasia; 2013 Dec; 15(12):1391-9. PubMed ID: 24403861
[TBL] [Abstract][Full Text] [Related]
49. [Experimental studies on the antitumor effect of progesterone and enhancement of the therapeutic effect of anticancer drugs by progesterone--from the aspect of zinc metabolism].
Ujiie S; Mimata Y; Okuno M; Wakui A
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2423-8. PubMed ID: 2751319
[TBL] [Abstract][Full Text] [Related]
50. [The principles of cancer treatment--changes in chemotherapy].
Sugimura T
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1263-78. PubMed ID: 12146011
[No Abstract] [Full Text] [Related]
51. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.
Ehnman M; Östman A
Expert Opin Investig Drugs; 2014 Feb; 23(2):211-26. PubMed ID: 24206431
[TBL] [Abstract][Full Text] [Related]
52. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice.
Zhang Y; Xiang L; Hassan R; Paik CH; Carrasquillo JA; Jang BS; Le N; Ho M; Pastan I
Clin Cancer Res; 2006 Aug; 12(15):4695-701. PubMed ID: 16899620
[TBL] [Abstract][Full Text] [Related]
53. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
Kłosowska-Wardega A; Hasumi Y; Burmakin M; Ahgren A; Stuhr L; Moen I; Reed RK; Rubin K; Hellberg C; Heldin CH
PLoS One; 2009 Dec; 4(12):e8149. PubMed ID: 19997591
[TBL] [Abstract][Full Text] [Related]
54. PDGF receptor blocker for pulmonary hypertension: a new agent in therapeutic arsenal.
Mathew R
Expert Opin Investig Drugs; 2012 Feb; 21(2):139-42. PubMed ID: 22217204
[No Abstract] [Full Text] [Related]
55. Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.
Rocchetti M; Del Bene F; Germani M; Fiorentini F; Poggesi I; Pesenti E; Magni P; De Nicolao G
Eur J Cancer; 2009 Dec; 45(18):3336-46. PubMed ID: 19854637
[TBL] [Abstract][Full Text] [Related]
56. [Inhibitory effect of tumor necrosis factor and interferon with chemotherapeutic drugs on the growth of cancer cell of tongue].
Qu XR; Shen ZH; He ZM
Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):421-2. PubMed ID: 12206026
[No Abstract] [Full Text] [Related]
57. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors.
Tunggal JK; Cowan DS; Shaikh H; Tannock IF
Clin Cancer Res; 1999 Jun; 5(6):1583-6. PubMed ID: 10389947
[TBL] [Abstract][Full Text] [Related]
58. PDGF-D signaling: a novel target in cancer therapy.
Wang Z; Kong D; Li Y; Sarkar FH
Curr Drug Targets; 2009 Jan; 10(1):38-41. PubMed ID: 19149534
[TBL] [Abstract][Full Text] [Related]
59. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis.
D'Andrea MR; Mei JM; Tuman RW; Galemmo RA; Johnson DL
Mol Cancer Ther; 2005 Aug; 4(8):1198-204. PubMed ID: 16093435
[TBL] [Abstract][Full Text] [Related]
60. Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.
Burmakin M; van Wieringen T; Olsson PO; Stuhr L; Åhgren A; Heldin CH; Reed RK; Rubin K; Hellberg C
J Transl Med; 2017 Feb; 15(1):47. PubMed ID: 28231806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
